MindWalk Holdings, Inc. (HYFT): Market Cap to Revenue

Symbol and logo of brand MindWalk Therapeutics (HYFT)

The price-to-sales trend in the data sequence on the GURU.Markets chart demonstrates the impact of IT infrastructure robotization to eliminate routine tasks, with the value recorded at 3.80. MindWalk Holdings generates revenue from digital healthcare and medical data analysis, as well as the acceleration of immunological drug development via Big Data, which determines the company's current market valuation.

MindWalk Holdings, Inc. (HYFT): Price-to-Revenue Ratio from 09/05/2025 to 11/17/2026

ipatherapeutics.com (HYFT) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
General company analysis:HYFT MindWalk Holdings, Inc.
Manufactured products of MindWalk Holdings

The development of the MindWalk Holdings (HYFT) AI ecosystem within the private healthcare sector ensures a steady revenue stream driven by high B2B customer retention. The P/S multiple correlates the company's total market capitalization with its sales volume, measuring the cost of each unit of revenue generated. A decrease in this ratio minimizes the risk of overpaying for the asset, although it may signal a slowdown in the industry's digitalization pace. By analyzing the P/S multiple trend, an investor assesses the fundamental attractiveness of the shares relative to the business's operational successes.

Competitors of MindWalk Holdings

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Market Capitalization-to-Revenue Ratio BHST|Invizyne Technologies - P/S Multiple|oramed.com (ORMP) - Market Cap to Revenue|ENTX (enterabio.com) - Market Cap to Revenue|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)